Vanguard Group Inc. Has $19.14 Million Stock Position in Organogenesis $ORGO

Key Points

• Vanguard Group Inc. increased its stake in Organogenesis by 23.4% during the first quarter, acquiring an additional 841,618 shares for a total ownership of 4,431,414 shares valued at approximately $19.14 million.
• Several institutional investors, including Mackenzie Financial Corp and Cerity Partners LLC, increased their stakes in Organogenesis, reflecting growing interest in the company's stock.
• Organogenesis reported a loss per share of ($0.09) in its last earnings report, missing analysts' expectations, with revenue of $101.01 million, below the forecast of $104.75 million.

Vanguard Group Inc. increased its holdings in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 23.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,431,414 shares of the company's stock after buying an additional 841,618 shares during the quarter. Vanguard Group Inc. owned about 3.49% of Organogenesis worth $19,144,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Mackenzie Financial Corp increased its position in shares of Organogenesis by 65.4% in the first quarter. Mackenzie Financial Corp now owns 126,303 shares of the company's stock worth $546,000 after acquiring an additional 49,950 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Organogenesis in the 1st quarter valued at $631,000. Victory Capital Management Inc. acquired a new stake in Organogenesis in the 1st quarter valued at $67,000. CWM LLC raised its position in Organogenesis by 8.9% in the first quarter. CWM LLC now owns 63,894 shares of the company's stock valued at $276,000 after purchasing an additional 5,239 shares during the period. Finally, Cerity Partners LLC lifted its stake in shares of Organogenesis by 48.2% during the first quarter. Cerity Partners LLC now owns 74,880 shares of the company's stock worth $323,000 after purchasing an additional 24,362 shares in the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Price Performance

ORGO traded up $0.10 during midday trading on Wednesday, hitting $5.00. 201,186 shares of the company's stock traded hands, compared to its average volume of 1,395,168. The company has a market cap of $633.79 million, a PE ratio of -35.53 and a beta of 1.75. The stock's fifty day simple moving average is $4.53 and its 200-day simple moving average is $4.20. Organogenesis has a one year low of $2.45 and a one year high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The business had revenue of $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%. Organogenesis has set its FY 2025 guidance at EPS. On average, research analysts expect that Organogenesis will post -0.07 EPS for the current year.

Insider Buying and Selling

In related news, insider Lori Freedman bought 142,379 shares of the business's stock in a transaction on Thursday, June 5th. The shares were bought at an average cost of $2.91 per share, for a total transaction of $414,322.89. Following the completion of the acquisition, the insider directly owned 837,437 shares in the company, valued at approximately $2,436,941.67. This represents a 20.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ORGO has been the subject of a number of recent research reports. BTIG Research reiterated a "buy" rating on shares of Organogenesis in a research note on Tuesday, July 15th. Cantor Fitzgerald boosted their price target on shares of Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $7.50.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.